{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:27:27Z","timestamp":1788460047803,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020439","name":"Jiangsu Pharmaceutical Association","doi-asserted-by":"crossref","award":["H202052, H202024 and H202011"],"award-info":[{"award-number":["H202052, H202024 and H202011"]}],"id":[{"id":"10.13039\/100020439","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100020439","name":"Jiangsu Pharmaceutical Association","doi-asserted-by":"crossref","award":["H202052, H202024 and H202011"],"award-info":[{"award-number":["H202052, H202024 and H202011"]}],"id":[{"id":"10.13039\/100020439","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100020439","name":"Jiangsu Pharmaceutical Association","doi-asserted-by":"crossref","award":["H202052, H202024 and H202011"],"award-info":[{"award-number":["H202052, H202024 and H202011"]}],"id":[{"id":"10.13039\/100020439","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"crossref","award":["320.6750.2020-4-37 and 320.6750.2020-12-69"],"award-info":[{"award-number":["320.6750.2020-4-37 and 320.6750.2020-12-69"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"crossref","award":["320.6750.2020-4-37 and 320.6750.2020-12-69"],"award-info":[{"award-number":["320.6750.2020-4-37 and 320.6750.2020-12-69"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Funds of Suzhou Municipality","award":["SYSD2020188"],"award-info":[{"award-number":["SYSD2020188"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and objective<\/jats:title>\n                <jats:p>Currently, the detection rates of methicillin-resistant S. aureus (MRSA) and methicillin-resistant coagulase-negative staphylococci (MRCoNS) in the blood cultures of neonates with sepsis exceed the national average drug resistance level, and vancomycin and linezolid are the primary antibacterial drugs used for these resistant bacteria according to the results of etiological examinations. However, a comprehensive evaluation of their costs and benefits in late-onset neonatal sepsis in a neonatal intensive care unit (NICU) has not been conducted. This study aimed to compare the cost and effectiveness of vancomycin and linezolid in treating neonatal sepsis in the NICU.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cost-effectiveness analysis of real-world data was carried out by retrospective study in our hospital, and the cost and effectiveness of vancomycin and linezolid were compared by establishing a decision tree model. The drug doses in the model were 0.6\u00a0g for linezolid and 0.5\u00a0g for vancomycin. The cost break down included cost of medical ward, NICU stay, intravenous infusion of vancomycin or linezolid, all monitoring tests, culture tests and drugs. The unit costs were sourced from hospital information systems. The effectiveness rates were obtained by cumulative probability analysis. One-way sensitivity analysis was used to analyze uncertain influencing factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The effectiveness rates of vancomycin and linezolid in treating neonatal sepsis in the NICU were 89.74% and 90.14%, respectively, with no significant difference. The average cost in the vancomycin group was \u00a512261.43, and the average cost in the linezolid group was \u00a517227.96. The incremental cost effectiveness was \u00a512416.33 cost per additional neonate with treatment success in the linezolid group compared to vancomycin group at discharge. Factors that had the greatest influence on the sensitivity of the incremental cost-effectiveness ratio were the price of linezolid and the effectiveness rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The cost for treatment success of one neonate in linezolid group was \u00a55449.17 more than that in vancomycin group, indicating that vancomycin was more cost-effective. Therefore, these results can provide a reference for a cost effectiveness treatment scheme for neonatal sepsis in the NICU.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-023-09628-9","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T14:02:52Z","timestamp":1689775372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A real-world cost-effectiveness study of vancomycin versus linezolid for the treatment of late-onset neonatal sepsis in the NICU in China"],"prefix":"10.1186","volume":"23","author":[{"given":"Linjun","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyun","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juehui","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lufen","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiantong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"issue":"1","key":"9628_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17512433.2020.1699790","volume":"13","author":"S Esposito","year":"2020","unstructured":"Esposito S, Principi N. Adjunctive therapy to treat neonatal sepsis. Expert Rev Clin Pharmacol. 2020;13(1):65\u201373.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"9628_CR2","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2214-109X(16)30334-5","volume":"5","author":"C He","year":"2017","unstructured":"He C, Liu L, Chu Y, Perin J, Dai L, Li X, Miao L, Kang L, Li Q, Scherpbier R, et al. National and subnational all-cause and cause-specific child mortality in China, 1996\u20132015: a systematic analysis with implications for the Sustainable Development Goals. Lancet Glob Health. 2017;5(2):e186\u201397.","journal-title":"Lancet Glob Health"},{"key":"9628_CR3","doi-asserted-by":"crossref","unstructured":"Tang XJ, Sun B, Ding X, Li H, Feng X. Changing trends in the bacteriological profiles and antibiotic susceptibility in neonatal sepsis at a tertiary children\u2019s hospital of China. Transl Pediatr. 2020;9(6):734\u201342.","DOI":"10.21037\/tp-20-115"},{"issue":"1","key":"9628_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12887-018-1176-x","volume":"18","author":"B Pokhrel","year":"2018","unstructured":"Pokhrel B, Koirala T, Shah G, Joshi S, Baral P. Bacteriological profile and antibiotic susceptibility of neonatal sepsis in neonatal intensive care unit of a tertiary hospital in Nepal. BMC Pediatr. 2018;18(1):208.","journal-title":"BMC Pediatr"},{"key":"9628_CR5","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2147\/DDDT.S164515","volume":"12","author":"SMR Hashemian","year":"2018","unstructured":"Hashemian SMR, Farhadi T, Ganjparvar M. Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther. 2018;12:1759\u201367.","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"9628_CR6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/INF.0000000000002619","volume":"39","author":"M Sicard","year":"2020","unstructured":"Sicard M, Moussa A, Barrington K, Martin B, Luu TM, Ting JY, Roberts A, Paquette V, Shah PS, Kelly E, et al. Neonatal and neurodevelopmental outcomes following linezolid for coagulase-negative staphylococcal infection: real world evidence. Pediatr Infect Dis J. 2020;39(7):598\u2013603.","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"9628_CR7","first-page":"686","volume":"54","author":"L Tang","year":"2016","unstructured":"Tang L, Fang J, Wang SN, Weng XH, Li JJ, Shang EN. Clinical efficacy and safety of vancomycin compared with linezolid for the treatment of neonatal gram-positive bacterial sepsis. Zhonghua Er Ke Za Zhi. 2016;54(9):686\u201391.","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"11","key":"9628_CR8","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1111\/bcp.14084","volume":"85","author":"N Sosnin","year":"2019","unstructured":"Sosnin N, Curtis N, Cranswick N, Chiletti R, Gwee A. Vancomycin is commonly under-dosed in critically ill children and neonates. Br J Clin Pharmacol. 2019;85(11):2591\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"9628_CR9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1089\/omi.2019.0113","volume":"23","author":"AM Voermans","year":"2019","unstructured":"Voermans AM, Mewes JC, Broyles MR, Steuten LMG. Cost-effectiveness analysis of a procalcitonin-guided decision algorithm for antibiotic stewardship using real-world u.s. hospital data. Omics. 2019;23(10):508\u201315.","journal-title":"Omics"},{"issue":"1","key":"9628_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40360-020-00424-3","volume":"21","author":"T Ueda","year":"2020","unstructured":"Ueda T, Takesue Y, Nakajima K, Ichiki K, Ishikawa K, Takai Y, Yamada K, Tsuchida T, Otani N, Takahashi Y, et al. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 \u03bcg\/mL using a regimen of 12 mg\/kg for five doses within the initial 3 days. BMC Pharmacol Toxicol. 2020;21(1):50.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"27","key":"9628_CR11","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.2217\/fon-2018-0321","volume":"14","author":"J Zhu","year":"2018","unstructured":"Zhu J, He W, Ye M, Fu J, Chu YB, Zhao YY, Zhang YJ, Kuo D, Wu B. Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. Future Oncol. 2018;14(27):2833\u201340.","journal-title":"Future Oncol"},{"issue":"3","key":"9628_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1742-1241.2008.01958.x","volume":"63","author":"M Bounthavong","year":"2009","unstructured":"Bounthavong M, Hsu DI, Okamoto MP. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. Int J Clin Pract. 2009;63(3):376\u201386.","journal-title":"Int J Clin Pract"},{"issue":"10","key":"9628_CR13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/myc.12801","volume":"61","author":"HHL Borba","year":"2018","unstructured":"Borba HHL, Steimbach LM, Riveros BS, Tonin FS, Ferreira VL, Bagatim BAQ, Balan G, Pontarolo R, Wiens A. Cost-effectiveness of amphotericin B formulations in the treatment of systemic fungal infections. Mycoses. 2018;61(10):754\u201363.","journal-title":"Mycoses"},{"issue":"2","key":"9628_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2217\/cer-2019-0075","volume":"9","author":"M Huang","year":"2020","unstructured":"Huang M, Tian Y, He M, Liu J, Ren L, Gong Y, Peng F, Wang Y, Ding Z, Wang J, et al. Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China. J Comp Eff Res. 2020;9(2):93\u2013102.","journal-title":"J Comp Eff Res"},{"key":"9628_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2147\/IDR.S191533","volume":"12","author":"AA El-Madbouly","year":"2019","unstructured":"El-Madbouly AA, El Sehemawy AA, Eldesoky NA, Abd Elgalil HM, Ahmed AM. Utility of presepsin, soluble triggering receptor expressed on myeloid cells-1, and neutrophil CD64 for early detection of neonatal sepsis. Infect Drug Resist. 2019;12:311\u20139.","journal-title":"Infect Drug Resist"},{"issue":"4","key":"9628_CR16","doi-asserted-by":"publisher","first-page":"e0215683","DOI":"10.1371\/journal.pone.0215683","volume":"14","author":"S Murthy","year":"2019","unstructured":"Murthy S, Godinho MA, Guddattu V, Lewis LES, Nair NS. Risk factors of neonatal sepsis in India: a systematic review and meta-analysis. PLoS ONE. 2019;14(4):e0215683.","journal-title":"PLoS ONE"},{"issue":"5","key":"9628_CR17","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jval.2015.04.007","volume":"18","author":"CD Collins","year":"2015","unstructured":"Collins CD, Schwemm AK. Linezolid Versus Vancomycin in the Empiric Treatment of Nosocomial Pneumonia: A Cost-Utility Analysis Incorporating Results from the ZEPHyR Trial. Value Health. 2015;18(5):614\u201321.","journal-title":"Value Health"},{"issue":"6","key":"9628_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s10096-019-03503-4","volume":"38","author":"C Rubio-Terr\u00e9s","year":"2019","unstructured":"Rubio-Terr\u00e9s C, Aguado JM, Almirante B, Cobo J, Grau S, Salavert M, Gonz\u00e1lez Antona S\u00e1nchez E, L\u00f3pez Guti\u00e9rrez C, Rubio-Rodr\u00edguez D. Extended-pulsed fidaxomicin versus vancomycin in patients 60\u00a0years and older with clostridium difficile infection: cost-effectiveness analysis in Spain. Eur J Clin Microbiol Infect Dis. 2019;38(6):1105\u201311.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"9628_CR19","doi-asserted-by":"publisher","first-page":"e16804","DOI":"10.2196\/16804","volume":"22","author":"J Powell","year":"2020","unstructured":"Powell J, Williams V, Atherton H, Bennett K, Yang Y, Davoudianfar M, Hellsing A, Martin A, Mollison J, Shanyinde M, et al. Effectiveness and cost-effectiveness of a self-guided internet intervention for social anxiety symptoms in a general population sample: randomized controlled trial. J Med Internet Res. 2020;22(1):e16804.","journal-title":"J Med Internet Res"},{"issue":"12","key":"9628_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.12968\/hmed.2017.78.12.699","volume":"78","author":"S Mitra","year":"2017","unstructured":"Mitra S, Rennie J. Neonatal jaundice: aetiology, diagnosis and treatment. Br J Hosp Med (Lond). 2017;78(12):699\u2013704.","journal-title":"Br J Hosp Med (Lond)"},{"issue":"4","key":"9628_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.siny.2008.02.009","volume":"13","author":"S Aher","year":"2008","unstructured":"Aher S, Malwatkar K, Kadam S. Neonatal anemia. Semin Fetal Neonatal Med. 2008;13(4):239\u201347.","journal-title":"Semin Fetal Neonatal Med"},{"issue":"8","key":"9628_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jiac.2016.05.003","volume":"22","author":"Y Hanai","year":"2016","unstructured":"Hanai Y, Matsuo K, Ogawa M, Higashi A, Kimura I, Hirayama S, Kosugi T, Nishizawa K, Yoshio T. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother. 2016;22(8):536\u201342.","journal-title":"J Infect Chemother"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09628-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-023-09628-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09628-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T14:04:06Z","timestamp":1689775446000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-023-09628-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["9628"],"URL":"https:\/\/doi.org\/10.1186\/s12913-023-09628-9","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"9 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was submitted to the Ethics Committee of the Affiliated Suzhou Hospital of Nanjing Medical University and ethical approval No. (L20129901). All methods were carried out in accordance with relevant guidelines and regulations. All participants signed informed consent form about voluntary participation in the study. For all participants who under 16\u00a0years of age, we obtained informed consent from their parents or legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"771"}}